Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amgen, Bioarctic, JCR, Medipal, Valneva, Viridian.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 2seventy, ALX, BMS, Cassava, Evotec, Gilead, Korro, Mira, Novavax, Peptone, Phosphorex, Rallybio, Ratio, Scenic, Vor.
New hires and promotions in the biopharma industry, including: Context, Eli Lilly, Novavax, Pathos AI, Phoremost, Revolution, Seamless, Sibylla, Synnovation.
In April, biopharma transactions amounted to $12.8 billion, a sharp decline from March’s $29.48 billion. However, with $79.66 billion in deal value during the first four months of 2025, the sector has already achieved its highest start to a year in BioWorld’s records since 2019.
Finding that a lower court went too far with an injunction that ignores the Hatch-Waxman safe harbor protections for drug development, the U.S. Court of Appeals for the Federal Circuit handed Avadel CNS Pharmaceuticals LLC a win of sorts.
As biopharma companies continue to roll out their first-quarter earnings, Trump administration tariffs remain at the top of investors’ minds. While executives offer their various strategies to appease concerns, the uncertainty prevails, making it difficult to clearly satisfy all of the questions.
The promise of mesenchymal stem cells (MSCs) to heal heart disease could be around the corner thanks to a new delivery method tested by regenerative medicine company Cynata Therapeutics Ltd.
Private biotechs in Switzerland raised CHF833 million (US$1.002 billion) in 2024, driving an overall increase in capital investment in the sector to $3 billion, up from $2.4 billion in 2023.
RSS
